Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

被引：0
作者：
Takeru Shiroiwa
Takashi Fukuda
Kojiro Shimozuma
Mitsuko Mouri
Yasuhiro Hagiwara
Takuya Kawahara
Shozo Ohsumi
Yasuo Hozumi
Yoshiaki Sagara
Yasuo Ohashi
Hirofumi Mukai
机构：
[1] Department of Health and Welfare Services,Department of Biomedical Sciences, College of Life Sciences
[2] National Institute of Public Health,Department of Biostatistics, School of Public Health
[3] Ritsumeikan University,Biostatistics Division, Clinical Research Support Center
[4] Kanagawa Academy of Science and Technology (KAST),Department of Breast and Endocrine Surgery
[5] The University of Tokyo,Department of Integrated Science and Engineering
[6] The University of Tokyo Hospital,undefined
[7] Department of Breast Oncology,undefined
[8] National Hospital Organization Shikoku Cancer Center,undefined
[9] University of Tsukuba Hospital,undefined
[10] Department of Breast Surgery,undefined
[11] Ibaraki Prefectural Central Hospital,undefined
[12] Breast Surgery Department,undefined
[13] Social Medical Corporation Hakuaikai Sagara Hospital,undefined
[14] Chuo University,undefined
[15] Division of Breast and Medical Oncology,undefined
[16] National Cancer Center Hospital East,undefined
来源：
BMC Cancer | / 17卷
关键词：
Cost-effectiveness analysis; Quality-adjusted life years; Breast neoplasms; Randomized controlled trial; S-1; Taxoids;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 158 条
[1]  
Burki TK(2016)NICE restructures the cancer drugs fund Lancet Oncol 17 e9-680
[2]  
Timmins N(2016)At last, NICE to take over the cancer drugs fund BMJ 352 i1324-466
[3]  
Squires H(2016)Trastuzumab Emtansine for treating HER2-positive, Unresectable, locally advanced or metastatic breast cancer after treatment with Trastuzumab and a Taxane: an evidence review group perspective of a NICE single technology appraisal PharmacoEconomics 34 673-148
[4]  
Stevenson M(2015)The clinical and cost effectiveness of Aflibercept in combination with Irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior Oxaliplatin-based chemotherapy: a critique of the evidence PharmacoEconomics 33 457-8
[5]  
Simpson E(2015)Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal PharmacoEconomics 33 137-98
[6]  
Harvey R(2003)S-1 in gastric cancer: a comprehensive review Gastric Cancer 6 2-984
[7]  
Stevens J(2016)Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial Lancet Oncol 17 90-1485
[8]  
Wade R(1998)Treatment of breast cancer N Engl J Med 339 974-72
[9]  
Duarte A(2015)Breast cancer, version 1.2016 J Natl Compr Cancer Netw 13 1475-353
[10]  
Simmonds M(1996)EuroQol: the current state of play Health Policy 37 53-533
12345678910